Connect with us

Spread & Containment

War: Big Inflation & Recession Shocks, Rates Are Smaller

(The Ukraine War) “means a bigger inflation shock, a smaller rates shock, and a bigger recession shock.” -Bank of America Corp. chief strategist Michael…

Published

on

(The Ukraine War) “means a bigger inflation shock, a smaller rates shock, and a bigger recession shock.” -Bank of America Corp. chief strategist Michael Hartnett, 3-4-22

The war triggers a huge surge in oil prices, consumer sentiment is already falling, and the Fed is likely to raise rates slowly because of the war.  We examine how: economic sanctions can cause inflation during wartime, consumer sentiment declining, real retail sales under pressure, GDP is weakening, and a unique oil price ratio to 10 – 2-year bond spread indicates a coming recession.

Severe Economic Sanctions Against Russia Enacted

After weeks of planning, as the Russian forces massed on the Ukraine border, it became evident to Western leaders that they must act.  During the first few days of the war, the European Union and the U.S. set in motion economic sanctions, including freezing significant oligarch assets in western banks, including Vladimir Putin’s assets, freezing four important Russian bank assets in the west, and cutting off Russian access to the inter-banking SWIFT system.  On March 8th, the U.S. placed an embargo on all Russian oil and gas imports. Plus, Russian planes are prohibited from landing in western airports.   

U.S. oil businesses have also acted with Chevron, BP, and ExxonMobil, ending their partnerships with their Russian partner companies. Apple and Microsoft have announced the freezing of all operations in Russia.  McDonald’s, Starbucks, PepsiCo, and Coca-Cola have suspended product sales and closed thousands of stores. Visa, Mastercard, and American Express have announced suspending transactions in and out of Russia, thus freezing a channel for Russians to move money out of the country.  The ruble has crashed to the lowest value versus the dollar in modern times, and the Russian stock exchange is closed. Next, we examine how major wars cause inflation to surge.

Wars Often Trigger Inflation

Major wars throughout history have caused massive dislocations, recessions, and depressions. These massive infrastructure losses of goods, services, food, water, and fuels trigger scarcity and result in inflation spikes. The following chart, courtesy of The Daily Shot, shows from the War of 1812 through WW II that prices shot up after each war.  The Vietnam War CPI increased from 1.4% in 1965 to 4.3% in 1971 based on a La Salle University analysis of the President’s Economic Report in 1982.  

Sources: Census Bureau, The Daily Shot – 3/4/22

Let’s look at how the allies’ sanctions may impact Western economies and Russia.

Russia is a Major Exporter of Key Commodities Triggering Inflation Surge

Russia is the third-largest oil producer globally and provides 40% of Europe’s natural gas.  The country is the world’s largest exporter of wheat and a significant exporter of fertilizer, gold, silver, palladium, and other rare earth metals.   The shortages already in place from the pandemic set world markets for most commodities at 10-year highs. Commodities are now set to hit all-time records.  The U.S. has announced an embargo on Russian oil, which JP Morgan analysts forecast would jump the price of Brent crude to $150 a barrel for Brent crude quickly.  The all-time high for Brent crude was $147.50 in 2008.  

Commodity prices are surging across global markets as traders seek out new supplies in a cascade of disruptions.  There are over 200 ships stuck at Ukrainian ports, and maritime historians report that more vessels are stranded globally than ever since WWII. The Bloomberg Commodity Index for last week jumped by 12.5%, a high not seen since the 1960s. Next, we look at the U.S. inflation picture. Before the war, inflation was already high in the U.S.  The loss of significant commodity imports added to an already high inflation rate will shock the economy.

Inflation Already at Ten Year High Soars

The U.S. is already experiencing a ten-year inflation high, with the CPI at 7.5% for January and energy is one of the key drivers of inflation. The following chart from the U.S. Bureau of Labor Statistics shows how energy (orange) costs, mainly oil drove the CPI increase.  It seems that shelter costs are underreported in this chart indicated at 7%. Yet, the Case-Shiller Housing Price Index has jumped 19% year over year, and rents have jumped 12% during a similar time frame.

inflation cpi war

Source: Bureau of Labor Statistics – 3/4/22

Recently, commodity prices have soared in the U.S. after the February 24th attacks started.  The following chart from the Chicago Board of Trade shows how metals and grains have surged in the past week.

price of grains and metals

Sources: The Chicago Board of Trade, Factset, The Wall Street Journal – 3/4/22

High inflation continues to hammer consumer sentiment.

Consumer Sentiment Decline Driving Retail Sales Down

Before the Russia – Ukraine War, consumers were already concerned about increasing food, shelter, and car prices as consumer sentiment dropped to a ten-year low. Now, the surge in inflation has been driving sentiment down further.  A Bloomberg Intelligence study shows that a one-cent change in gas prices influences $1.1B in consumer fuel spending.  The following chart from the University of Michigan shows how far consumer sentiment for February has dipped recently to 61.7.

michigan consumer sentiment war

Sources: University of Michigan, Bloomberg – 2/11/22

Consumer sentiment can indicate the direction of retail sales, a significant component of GDP.  The following chart, courtesy of The Daily Shot, shows how retail sales track consumer sentiment over three-month periods.  The sentiment (blue line) has recently fallen below zero, adding to a retail sales decline.

retail sales sentiment

Source: The Daily Shot – 2/14/22

Retail sales have gone up on a nominal basis, but actual spending has dropped when retail sales are adjusted for inflation.  The following analysis by EPB Macro Research uses a 6-month smoothed growth rate of retail sales. The report shows how real retail sales have fallen below zero and sit on the zero line.

real retail sales

Sources: Census Bureau, Bureau of Labor Statistics, EPB Macro Research – 1/31/22

Retail sales include final goods, both durable and non-durable, and consumer services.  Further, consider, consumer spending is about 70% of GDP. Therefore, retail sales are a good indicator of GDP direction.  Forecasts are indicating a weakening GDP for the first quarter of 2022.

GDP 1st Quarter 2022 Forecast Approaches Zero

The Atlanta Federal Reserve GDPNow estimate shows GDP about zero for the 1st quarter of 2022. Its GDPNow model is an estimate based on a computer model with inputs from various reports throughout the month, including Wholesale Trade, Monthly Retail Report, Personal Income and Outlays, Manufacturing ISM Report, Durable Goods Report, Residential Construction, and several others.  The report updates appear about 6 or 7 times a month.  The report data was before the Russia – Ukraine War. 

atlanta fed gdpnow GDP

Source: Atlanta Federal Reserve – 3/1/22

Based on the shock to the U.S. and the world economy from the war, we expect many of the GDPNow model’s components will begin to show weakness besides the already mentioned decline in retail sales.  Finally, a unique analysis of oil prices and 10 – 2 year bond spreads indicates a likely recession.

Oil Price – Bond Model Indicates Likely Recession

As the WTI crude oil price approaches $130 a barrel and beyond, and insightful by Cory Venable of Venable Park Investment. He uses a ratio of oil prices to 10 – 2-year bonds to indicate a possible recession in 6 – 12 months.  The model has a good record of success in forecasting recessions 1990, 2000, 2007, and 2020.  His partner Danielle Park introduces the model to provide you with more detail.  This model uses a WTI oil price at $92 per barrel. Now that oil prices have surged, the model should dive even further, confirming the coming weakness in the economy.

treasury yield curve gdp

Source: Danielle Park – 2/10/22

The uncertainty and new financial order globally are likely to last as Russia pursues its vision of the pre-Soviet Russian Empire.

Putin Not Likely to Shift Views – 30-Yr Economic Order Is Over

Vladimir Putin has set his sights on bringing Ukraine into the Russian orbit of countries. Brookings Institution Russia analyst Fiona Hill observes that Putin sees NATO creeping closer to Russia, so he feels like his country is under siege. He wants to push back while creating a Russian Empire that he believes existed centuries ago. She notes he is adamite about holding to this vision at all costs. The economic sanctions just feed his belief that the West is out to get him.

The proud Ukrainian people have fought the Russian attacks with courage, boldness, and ingenuity.  The outcome is unclear, except that the past 30-year order in Europe is over.  Sanctions between the West and Russia have triggered an economic war sweeping in third-world countries forcing them to choose sides. Further, the U.S. has targeted Chinese companies doing business with Russia in violation of sanctions.  If these firms defy the sanctions, they are threatened with the end of U.S. business sales.

Shifting Economic Flows Means a Recession is In View

We see inflation shock surging due to shortages and dislocations, driving a recession shock.  Despite the problems, the Federal Reserve seems concerned about the slowing economy and will likely only increase rates in small increments. Fed Chairman Jerome Powell announced that the Fed would raise rates slowly. He said a rate of only.25% is planned for their March 16th meeting. Thus, inflation will surge until consumers quit spending and the economy slows.

The war is shifting economic flows of goods, services, and finance into uncharted territory with consequences that are at best uncertain and at worst dangerous. Accordingly, fear, doubt, and uncertainty replace peace, order, and economic integration with Russia. The result of this catastrophic shift in financial relationships will be felt for years to come. 

Patrick Hill is the Editor of The Future Economy, the site hosts analysis of the real economy, ideas on a new economy, indicators, labor-capitalism trends, and posts to start a dialog. He writes from the heart of Silicon Valley, leveraging 20 years of experience as an executive at firms like H.P., Genentech, Verigy, Informatica, and Okta to provide investment and economic insights. Twitter: @PatrickHill1677, email: patrickhill@thefutureconomy.com

The post War: Big Inflation & Recession Shocks, Rates Are Smaller appeared first on RIA.

Read More

Continue Reading

Government

40,000 National Guard Troops Face Unemployment As Vaccine Deadline Imminent

40,000 National Guard Troops Face Unemployment As Vaccine Deadline Imminent

Up to 40,000 Army National Guard troops – around 13% of the force…

Published

on

40,000 National Guard Troops Face Unemployment As Vaccine Deadline Imminent

Up to 40,000 Army National Guard troops - around 13% of the force - could be fired for not getting the mandated COVID-19 vaccine (which has limited efficacy against Omicron, doesn't stop transmission, has been linked to elevated heart problems, and has been mandated for a healthy demographic that rarely dies of the disease).

Michigan Army National Guard Sgt. Mark Abbott administers a COVID-19 vaccine

Guard soldiers have until Thursday to get the jab, according to the Associated Press, which notes that between 20% and 30% of Guard soldiers in six states remain unvaccinated.

"We’re going to give every soldier every opportunity to get vaccinated and continue their military career. Every soldier that is pending an exemption, we will continue to support them through their process," Lt. Gen. Jon Jensen, director of the Army National Guard, told AP. "We’re not giving up on anybody until the separation paperwork is signed and completed. There’s still time."

Last year, Defense Secretary Lloyd Austin ordered all service members to get the vaccine, with different branches maintaining different deadlines for the jab. The Army National Guard was given the maximum amount of time, largely because its roughly 330,000 soldiers are scattered throughout the country, including remote locations.

The Army Guard’s vaccine percentage is the lowest among the U.S. military — with all the active-duty Army, Navy, Air Force and Marine Corps at 97% or greater and the Air Guard at about 94%. The Army reported Friday that 90% of Army Reserve forces were partially or completely vaccinated.

The Pentagon has said that after June 30, Guard members won’t be paid by the federal government when they are activated on federal status, which includes their monthly drill weekends and their two-week annual training period. Guard troops mobilized on federal status and assigned to the southern border or on COVID-19 missions in various states also would have to be vaccinated or they would not be allowed to participate or be paid. -AP

Complicating matters is a rule that Guard soldiers deployed on state active duty may not require a vaccination, depending on state-level mandates. 

According to the report, at least seven governors have asked Austin to reconsider, or drop, the vaccine mandate for National Guard members - with some having filed or joined lawsuits to that end.

Austin, apparently following his own special brand of science, told them to pound sand, saying that Covid-19 "takes our service members out of the fight, temporarily or permanently, and jeopardizes our ability to meet mission requirements," adding that troops will either need to get vaccinated or lose their Guard status.

"When you’re looking at, 40,000 soldiers that potentially are in that unvaccinated category, absolutely there’s readiness implications on that and concerns associated with that," said Jenson, adding "That's a significant chunk." 

AP reports that around 85% of Army Guard soldiers are fully vaccinated, while 87% are at least partially vaccinated.

Tyler Durden Sun, 06/26/2022 - 18:00

Read More

Continue Reading

Government

CDC Confirmed Post-Vaxx Death From Blood-Clotting Two Weeks Before Alerting Public: Emails

CDC Confirmed Post-Vaxx Death From Blood-Clotting Two Weeks Before Alerting Public: Emails

Authored by Zachary Stieber via The Epoch Times…

Published

on

CDC Confirmed Post-Vaxx Death From Blood-Clotting Two Weeks Before Alerting Public: Emails

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

The Centers for Disease Control and Prevention (CDC) confirmed in late 2021 that a person died from blood clotting after receiving a COVID-19 vaccine that had been linked with an increased risk of blood clotting, but did not alert the public for two weeks, newly obtained emails show.

A general view of the Centers for Disease Control headquarters in Atlanta, Ga., on April 23, 2020. (Tami Chappell/AFP via Getty Images)

Dr. Tom Shimabukuro, a CDC official, told colleagues at the CDC and the Food and Drug Administration (FDA) on Dec. 2, 2021, “We have confirmed a 9th TTS death following Janssen vaccination,” according to emails obtained by The Epoch Times through a Freedom of Information Act request.

TTS refers to thrombosis with thrombocytopenia syndrome, a condition that features low platelet levels combined with blood clots.

Officials had recommended a nationwide pause on the administration of the vaccine, produced by Johnson & Johnson (J&J) subsidiary Janssen, in April 2021 after six women experienced TTS after J&J vaccination and three died. But they lifted the pause after determining the vaccine remained safe and effective.

The condition was not discussed much in the ensuing months, despite the CDC later reporting that five additional deaths occurred before Aug. 31, 2021. Shimabukuro gave a single update, in mid-October 2021, saying five total deaths had been reported.

That was until December 2021. Twelve days after Shimabukuro alerted colleagues of the ninth death, the FDA urged healthcare workers not to administer the vaccine to people with certain conditions because of the TTS risk. Two days after that, Dr. Isaac See, another CDC official, informed the public during a meeting that nine deaths had occurred post-vaccination.

It’s unclear when the CDC learned of the sixth, seventh, and eighth deaths.

The CDC takes reports made to the Vaccine Adverse Event Reporting System and attempts to confirm the reports, including post-vaccination deaths. A higher number of post-vaccination TTS deaths have been reported to the system than the number the CDC has verified.

One day after Shimabukuro confirmed the ninth death, his message was forwarded by Dr. Amanda Cohn, another CDC official, to CDC Director Dr. Rochelle Walensky.

“See below, information on a 9th completely tragic death from TTS,” Cohn wrote.

Many thanks for letting us know … any tragic case,” Walensky responded.

The emails were partially redacted; one was fully redacted.

Read more here...

Tyler Durden Sun, 06/26/2022 - 15:30

Read More

Continue Reading

Spread & Containment

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) Breaking Out as Biotech Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) is moving steadily northbound with power after the Company reported Brilacidin, its defensin-mimetic drug…

Published

on

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) is moving steadily northbound with power after the Company reported Brilacidin, its defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity, inhibited the Omicron and Delta variants of SARS-CoV-2 based on in vitro testing conducted in collaboration with (NIH) and (NIAID) scientists. Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma and Alpha variants of SARS-CoV-2. Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested, independent of cell type, at generally attainable systemic concentrations (based on established human pharmacokinetics of IV-administered Brilacidin).  

Emerging SARS-CoV-2 variants, and increasingly their sub-variants, contain immunity-evading mutations. These mutations alter key parts of the SARS-CoV-2 spike protein that attach to human cells, making the virus more transmissible and potentially more virulent. Unlike other antivirals, such as monoclonal antibodies, and most vaccines, Brilacidin has been shown not to target the Spike S1 and Spike RBD regions of SARS-CoV-2, acting instead through dual-acting neutralizing and blocking antiviral properties, able to target virus and host. These antiviral traits support Brilacidin’s ability to maintain its anti-coronavirus activity and suggest Brilacidin would be less subject to resistance. Taken together, the results from NIH/NIAID testing of Brilacidin are supportive of previously completed research and give the Company confidence in the compound’s antiviral potential. The Company remains active in pursuing additional government-based funding opportunities, as well as licensing partnerships, to advance Brilacidin in the highly attractive area of developing novel broad-spectrum medicines for treating viral diseases. Microcapdaily has been reporting on IPIX for a long time and we were there when the stock (then trading as CTIX) made a legendary run skyrocketing to $4.93 per share. 

Subscribe To Our 100% Free Penny Stock Newsletter!

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) is a clinical stage pharmaceutical company developing innovative therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The Company owns the rights to Brilacidin, its lead drug in a new class of compounds called defensin-mimetics, and Kevetrin (thioureidobutyronitrile), its anti-cancer compound. Brilacidin is being studied by the Company, as well as other independent researchers, as a potential broad-spectrum antiviral therapeutic for the treatment of viruses including the novel coronavirus (SARS-CoV-2), which is responsible for COVID-19. 

Brilacidin is Innovation Pharma’s lead drug candidate in its Host Defense Protein (HDP)-mimetic franchise. Brilacidin has been granted Fast Track designation by the FDA and currently is being evaluated in a randomized, placebo-controlled Phase 2 clinical trial in hospitalized COVID-19 patients (see NCT04784897). Two independent Machine Learning (AI) studies also identified Brilacidin as one of the most promising inhibitors of SARS-CoV-2, the virus responsible for COVID-19, based on Brilacidin’s molecular properties. Modeled after HDPs, the “front-line” of defense in the body’s innate immune system, it is a synthetic, non-peptidic small molecule that kills pathogens swiftly, significantly reducing the likelihood of drug resistance developing. Just as importantly, Brilacidin functions in a robust immunomodulatory capacity, lessening inflammation and promoting healing. 

Kevetrin is a small molecule that has demonstrated the potential of becoming a breakthrough cancer treatment by inducing activation of p53, a protein frequently referred to as the “Guardian of the Genome” due to its critical role in controlling cell mutations. In most cancers, regardless of origin, type, and location, the p53 pathway becomes inactivated (dysfunctional), thus preventing the body from performing its natural anti-tumor functions. The TP53 gene is the most studied gene of all time. Conducted at the Dana-Farber Cancer Institute and at Beth Israel Deaconess Medical Center, a Phase 1 clinical trial evaluating Kevetrin in treating Advanced Solid Tumors has been successfully completed, with patients showing good toleration and encouraging signs of potential therapeutic response. The Company has concluded its open-label, dose-escalation Phase 2a trial of Kevetrin in Platinum-Resistant/Refractory Ovarian Cancer. Highly encouraging preliminary data from the first patients treated in the trial showed modulation of the p53 protein in response to administration of Kevetrin. With a promising bioavailability profile, and to leverage its short half-life (the drug exits the body in approximately 8 to 10 hours), efforts are underway to develop Kevetrin as an oral anti-cancer agent (tablet or capsule) that can be administered daily, potentially even multiple times per day. The FDA has awarded Kevetrin Orphan Drug status for Ovarian Cancer, Pancreatic Cancer, and Retinoblastoma, qualifying it for developmental incentives and an extra 7 years of market exclusivity upon drug approval. The FDA also has granted Kevetrin Rare Pediatric Disease designation for childhood Retinoblastoma. 

Microcapdaily has been covering IPIX for years starting with CTIX back in 2015 reporting on the stocks legendary run to $4.93 per share. We stated on CTIX back in the day: “As anyone in the industry knows, regulating the p53 pathway has long been the holy grail of cancer research and big pharma has spent hundreds of millions of dollars researching ways to achieve this with no success thus far. It seems Kevetrin(TM) has accomplished this; extensive preclinical research on Kevetrin shows the re-activation of p53 across a wide spectrum of cancer lines including colon, lung, breast and pancreatic cancers. The market potential for Kevetrin in treating drug-resistant cancers is worth $5 billion a year. Other cancers could easily represent an additional $5 billion annually, he adds.”

IPIX has established a valuable intellectual property portfolio: 

To Find out the inside Scoop on IPIX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

IPIX

On June 23 IPIX reported Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity, inhibited the Omicron (B.1.1.529) and Delta (B.1.617.2) variants of SARS-CoV-2 based on in vitro testing conducted in collaboration with National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) scientists. Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma (P.1) and Alpha (B.1.1.7) variants of SARS-CoV-2. Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested, independent of cell type, at generally attainable systemic concentrations (based on established human pharmacokinetics of IV-administered Brilacidin). Identifying COVID-19 countermeasures with novel mechanisms of action is vital. SARS-CoV-2 continues to evolve at an accelerated pace, raising questions as to what the dominant variant (or sub-variant) may be this fall and winter, when infections often spike — and if today’s COVID-19 vaccines and therapeutics can maintain their effectiveness. 

Emerging SARS-CoV-2 variants, and increasingly their sub-variants, contain immunity-evading mutations. These mutations alter key parts of the SARS-CoV-2 spike protein that attach to human cells, making the virus more transmissible and potentially more virulent. Unlike other antivirals, such as monoclonal antibodies, and most vaccines, Brilacidin has been shown not to target the Spike S1 and Spike RBD regions of SARS-CoV-2, acting instead through dual-acting neutralizing and blocking antiviral properties, able to target virus and host. These antiviral traits support Brilacidin’s ability to maintain its anti-coronavirus activity and suggest Brilacidin would be less subject to resistance. Related, results from new NIH/NIAID in vitro testing of Brilacidin in over 20 acutely infectious viruses, and from the Brilacidin Phase 2 COVID-19 clinical trial, are being prepared for publication. Findings from the Rutgers’ Brilacidin research can be accessed at the link below1 and build on earlier published Brilacidin research conducted by scientists at George Mason University and at University of Arizona and University of California-San Francisco. 

In 2021, the Company completed a Phase 2 clinical trial of Brilacidin (NCT04784897) for treatment of moderate-to-severe COVID-19 patients. While the trial did not meet its primary endpoint in reducing time to sustained recovery through day 29, certain patient subgroups did show treatment benefits of Brilacidin for that primary endpoint. For example, patients treated early from onset of symptoms achieved sustained recovery more quickly (Brilacidin 5-dose group vs pooled placebo, p=0.03). To date, only a modicum of success has been demonstrated by any company conducting clinical trials in moderate-to-severe hospitalized cases of COVID-19. A possible reason for this may be owing to frequent changes in the standard of care with patients receiving a cocktail of fluctuating concomitant medications, which complicates the interpretation of the clinical trial data and that of the new drug candidate being evaluated. Clinical observations of COVID-19 patients treated with Brilacidin further lead us to believe that higher and more frequent dosing of Brilacidin may be more appropriate to tackle this complex disease in the hospital setting. 

Taken together, the results from NIH/NIAID testing of Brilacidin are supportive of previously completed research and give the Company confidence in the compound’s antiviral potential. The Company remains active in pursuing additional government-based funding opportunities, as well as licensing partnerships, to advance Brilacidin in the highly attractive area of developing novel broad-spectrum medicines for treating viral diseases. 

For More on IPIX Subscribe Right Now!

Currently trading at an $18 million market valuation IPIX has $8.7 million in the treasury, over $11 million in assets vs. $4.5 million in total liabilities. IPIX is CTIX reincarnated and this stock can move skyrocketing to $4.93 per share back in the day; a run we reported on from the beginning. IPIX is heating up and getting noticed by investors after the Company reported Brilacidin, its defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity, inhibited the Omicron and Delta variants of SARS-CoV-2 based on in vitro testing conducted in collaboration with (NIH) and (NIAID) scientists. Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma and Alpha variants of SARS-CoV-2. Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested, independent of cell type, at generally attainable systemic concentrations (based on established human pharmacokinetics of IV-administered Brilacidin). We will be updating on IPIX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with IPIX.

WAIT! Do You Want Stocks That Could Go Up 348% In Days Delivered To Your Inbox For FREE?

Disclosure: we hold no position in IPIX either long or short and we have not been compensated for this article.

The post Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) Breaking Out as Biotech Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing first appeared on Micro Cap Daily.

Read More

Continue Reading

Trending